

> Measurements


# LIPID DISORDERS

Measurements

• Lipoproteins = lipids (cholesteryl esters & triglycerides) + phospholipids + proteins

include: chylomicrons, VLDL, IDL, LDL, HDL, Lp(a)

• Measure after 12-h fast; LDL typically calculated: LDL-C = TC – HDL-C – (TG/5) underestim. if TG >400 or LDL-C <70 mg/dL; ∴ directly measure LDL-C

levels stable up to 24 h after ACS, then ↓ and may take 6 wk to return to 正常

• PEx clues: tendon xanthomas (eg, Achilles), imply LDL >300 mg/dL; eruptive xanthomas on extensor surfaces imply TG >1000 mg/dL; xanthelasma (yellowish streaks on eyelids)

• Metabolic syndrome (≥3 of following): waist ≥40″ (♂) or ≥35″ (♀); TG ≥150; HDL <40 mg/dL (♂) or <50 mg/dL (♀); BP ≥130/85 mmHg; fasting glc ≥100 mg/dL (_Circ_ 2009;120:1640)

• Lp(a) = LDL particle bound to apo(a) via apoB; genetic variants a/w MI (_NEJM_ 2009;361:2518)

Dyslipidemias

• 1°: _familial hyperchol._ (FH, 1:500): defective LDL receptor; ↑↑ chol, 正常 TG; ↑ CAD; _familial hypertrig._ (FHTG, 1:500): ↑ TG, ± ↑ chol, ↓ HDL, pancreatitis; and many others

• 2°: DM (↑ TG, ↓ HDL), hypothyroidism (↑ LDL, ↑ TG), nephrotic syndrome (↑ LDL, ↑ TG), liver failure (↓ LDL), alcohol (↑ TG, ↑ HDL), thiazides (↑ LDL, ↑ TG), protease inhib (↑ TG)

![](https://i.imgur.com/kVthbrV.jpg)

Resins ↓ LDL-C by ~20%, but not well tolerated; niacin ↑ HDL-C and ↓ TG & LDL-C; no effect on CV outcomes.

治療 of LDL-C (_Lancet_ 2014;384:607)

• **Statins:** every 1 mmol (39 mg/dL) ↓ LDL-C → 22% ↓ major vascular events (CV death, MI, stroke, revasc) in individuals with & without CAD (_Lancet_ 2010;376:1670)

• **Ezetimibe:** ↓ major vascular events incl MI & stroke when added to statin post-ACS, with magnitude of benefit consistent with LDL-statin relationship (IMPROVE-IT, _NEJM_ 2015;372:2387)

• **PCSK9 inhibitors:** ~60% ↓ LDL-C on top of statin, as monoRx, and in FH (_EHJ_ 2014;35:2249); ↓ CV outcomes (_NEJM_ 2017;376:1713 & 2018;379:2097)

治療 of other lipid fractions (_Lancet_ 2014;384:618 & 626)

• **HDL-C:** low levels a/w ↑ risk of MI, but no 臨床benefit shown by raising

• **Triglycerides:** reasonable to treat levels >500–1000 mg/dL with fibrates or Ω-3 FA to ↓ risk of pancreatitis; genetically-mediated lower levels a/w ↓ risk of CAD (_NEJM_ 2014;371:22); modest benefit of fibrates on CV outcomes (_NEJM_ 2010;362:1563 & 2013;368:1800); high-dose Ω-3 FA (4 g/d of EPA) ↓ CV outcomes in 病人 with ASCVD or DM (_NEJM_ 2019:380:11)

• **Lp(a):** consider ↓ to <50 mg/dL in intermed- to high-risk 病人 (_EHJ_ 2010;31:2844)

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>2018 ACC/AHA Cholesterol Guidelines</b> <span>(</span><span><i>Circ</i></span> <span>20</span><span>1</span><span>9;</span><span>1</span><span>39:</span><span>e</span><span>1</span><span>082</span><span>)</span></p></td></tr><tr><td colspan="2"><p><b>Population</b></p></td><td><p><b>Recommendation</b></p></td></tr><tr><td colspan="2"><p>Very high-risk ASCVD<a id="st13"></a><a href="text/part0012_split_005.html#sst13">*</a></p></td><td><p>High-intensity statin; add EZE then PCSK9i if LDL-C ≥70</p></td></tr><tr><td colspan="2"><p>臨床ASCVD</p></td><td><p>High-intensity statin (? mod if &gt;75 y), add EZE if LDL-C ≥70</p></td></tr><tr><td colspan="2"><p>LDL-C ≥190 mg/dL</p></td><td><p>High-intensity statin; add EZE or PCKS9i if LDL-C ≥100</p></td></tr><tr><td colspan="2"><p>DM, age 40–75 y</p></td><td><p>High-intensity statin (? moderate if no CV RFs)</p></td></tr><tr><td rowspan="4"><p>Age 40–75 y (and none of above); <i>calc 10-y risk</i></p></td><td><p>≥20%</p></td><td><p>High-intensity statin</p></td></tr><tr><td><p>7.5%–&lt;20%</p></td><td><p>Moderate-intensity statin; if uncertain consider CAC</p></td></tr><tr><td><p>5–&lt;7.5%</p></td><td><p>Moderate-intensity statin reasonable</p></td></tr><tr><td><p>&lt;5%</p></td><td><p>Emphasize lifestyle</p></td></tr></tbody></table>

ASCVD incl h/o ACS, stable angina, art. revasc, stroke, TIA, PAD. [\*](text/part0012_split_005.html#st13)Multiple major ASCVD events (MI, stroke, sx PAD) or 1 major event + multiple high-risk conditions (age ≥65, DM, HTN, CKD, smoking, FH, prior PCI/CABG). 10-y CV Risk Score: [http://my.americanheart.org/cvriskcalculator](http://my.americanheart.org/cvriskcalculator). Additional risk factors to consider: LDL-C ≥160 mg/dl, met. synd.,CKD, FHx premature ASCVD, hsCRP ≥2 mg/l, Lp(a) ≥50 mg/dl, ABI <0.9, high-risk ethnic groups.

![](https://i.imgur.com/jG1GuNK.jpg)
